Tarsus Pharmaceuticals, Inc. Common Stock (TARS) is a publicly traded Healthcare sector company. As of May 21, 2026, TARS trades at $64.79 with a market cap of $2.70B and a P/E ratio of -56.22. TARS moved +5.71% today. Year to date, TARS is -18.76%; over the trailing twelve months it is +44.36%. Its 52-week range spans $31.36 to $85.25. Analyst consensus is strong buy with an average price target of $95.17. Rallies surfaces TARS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tarsus Doses First Participant in 700-Subject Phase 2 Lyme Prevention Trial: Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, enrolling roughly 700 adults to evaluate safety, tolerability and pharmacokinetics. Enrollment is slated to complete during the 2026 tick season with topline results expected in H1 2027 after Phase 2a data showed over 90% tick kill.
| Metric | Value |
|---|---|
| Price | $64.79 |
| Market Cap | $2.70B |
| P/E Ratio | -56.22 |
| EPS | $-1.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $85.25 |
| 52-Week Low | $31.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $535.08M |
| Net Income | $-48.27M |
| Gross Margin | 0.00% |
8 analysts cover TARS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.17.